Fungal Ruby - Taiwan Antrodia Cinnamomea International Academic Market Development Seminar Successfully Held in Hong Kong

On August 26, 2023, the Chinese Medicinal Fungi Industry Research and Development Association held the "Fungus Ruby - Taiwan Antrodia Cinnamomea International Academic Market Development Seminar" at the W Hotel in Hong Kong. The seminar brought together numerous experts and scholars from the biotechnology and Antrodia Cinnamomea industries for discussions and exchange.

Mr. Niu Xusheng, General Manager of Guangzhou Baoquan Biotech, served as the moderator of the meeting and introduced the guests one by one. Mr. Lu Zhenyu, Chairman of the China Medicinal Fungi Industry Research and Development Association, delivered a welcome speech.

Industry Experts

At the meeting, Zhang Haifeng, director and researcher of the Sino-Foreign Traditional Medicine Exchange Center and a senior Chinese health manager, shared his views on seven aspects: legal and policy support, a vast market, industry scale, high-tech, technical specifications and product standards, the entire industrial chain, empowered industries, and international cooperation. He elaborated on the forward-looking and extensive development of the Antrodia cinnamomea industry market.

Zhang Haifeng noted that the central government, the General Office of the State Council, and local governments have all enacted relevant laws and policies to support the vigorous development of the Traditional Chinese Medicine (TCM) industry, providing legal support and policy guarantees. In today's world, with rising living standards and changing lifestyles, people's demands for health are also increasing. This has led to a growing consumer base for Antrodia cinnamomea, increasing market demand, and promising market prospects. According to relevant data, although Antrodia cinnamomea is in a rapid development stage, its production volume is still far from meeting market demand compared to other fungal products. To break the traditional perception that Antrodia cinnamomea can only grow in the mountainous forests of Taiwan (450-2000 meters above sea level), and only grows on the inner wall of the decaying heartwood of the trunks of the unique Antrodia cinnamomea trees that are over 100 years old or on the moist surface of dead and fallen Antrodia cinnamomea trees, the team of renowned Taiwanese biotechnology expert Liu Yanhong has not only explored successful experience in cultivating Antrodia cinnamomea in plain areas through high-tech, but also opened up an industrial path for implementing standardized, intensive, large-scale management and product information traceability. This has laid a solid foundation for providing raw materials with stable production and reliable quality for the deep processing of Antrodia cinnamomea.

Next, we should build a full industrial chain to achieve deep integration of production, education, research and medical application of Antrodia cinnamomea, and create a high-quality development demonstration science and technology park for Antrodia cinnamomea; empower the industry, and China will implement a number of measures to create an international brand IP for Chinese Antrodia cinnamomea; and carry out international cooperation, actively cooperate with ASEAN countries, Eurasian Economic Association countries, Central Asian countries, Middle Eastern countries, etc., explore new development models, cooperate with ISO (International Organization for Standardization) to formulate and promulgate international standards for Antrodia cinnamomea, build a national-level "Belt and Road" Antrodia cinnamomea joint laboratory in the field of traditional Chinese medicine, and expand Antrodia cinnamomea's market share in domestic and foreign traditional Chinese medicine markets.

Guest Sharing

At the meeting, CS Group President Huang Sihao also introduced the origin and development of Antrodia cinnamomea, explaining its value and current problems.

Chief Technology Officer Liu Yanhong and Dr. Hong Tangyao, renowned Taiwanese biotechnology experts, demonstrated the patented technologies and key ingredients of Antrodia cinnamomea technology development. The team achieved significant breakthroughs in Antrodia cinnamomea cultivation and other technical aspects. Through the three core cultivation technologies of strains, carriers, and testing, the appearance and ingredients of cultivated Antrodia cinnamomea are exactly the same as those of wild mushrooms, and have passed authoritative testing. Antrodia cinnamomea's unique anthelmintic acid component has multiple benefits, but it also faces the characteristics of high efficacy requirements, insufficient yield, and difficulty in extraction. The team's technology has solved these problems, transforming Antrodia cinnamomea from wild harvesting to technical cultivation and production, realizing extraction production.

Industry-integrated capital

Dr. Qiao Li (PhD, School of Economics and Management, Tsinghua University), an expert on CS Group's IPO team, explained the connection between Antrodia cinnamomea and the ESG industry from the perspective of industry-integrated capital and reported on CS Group's progress in promoting ESG industry listings. CS Group's integration into the Antrodia cinnamomea industry will lead to new changes in its valuation model, and its stock price will undoubtedly reflect this positively.

Finally, Attorney Huang Huipeng also reported on the financial and legal status of CS Group over the past three years. He also expressed full confidence in the group's successful listing with the US SEC and future transfer to the main board. The future is promising!

During the discussion session, all guests actively discussed and researched Antrodia cinnamomea, expressing their affirmation of its market prospects and enthusiasm for cooperation.

Link to report

https://mp.weixin.qq.com/s/Rkr5arIvaEh0TMBL_XoBkQ